Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Erica S. Tsang ◽  
Janine M. Davies ◽  
Jonathan M. Loree ◽  
Howard J. Lim ◽  
Daniel J. Renouf ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

2013 ◽  
Vol 49 (16) ◽  
pp. 3412-3419 ◽  
Author(s):  
Jordi Bruix ◽  
Won-Young Tak ◽  
Antonio Gasbarrini ◽  
Armando Santoro ◽  
Massimo Colombo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Phase Ii ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Open Label ◽  
Second Line Therapy ◽  
Safety Study ◽  
Line Therapy ◽  
Open Label Phase

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

2016 ◽  
Vol 65 (2) ◽  
pp. 280-288 ◽  
Author(s):  
Michael Bitzer ◽  
Marius Horger ◽  
Edoardo G. Giannini ◽  
Tom M. Ganten ◽  
Marcus A. Wörns ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration

2016 ◽  
Vol 27 ◽  
pp. vi238 ◽  
Author(s):  
Y.-Y. Shao ◽  
B.-B. Chen ◽  
Z.-Z. Lin ◽  
C.-H. Hsu ◽  
M.-J. Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document